Answers are grounded in this paper and cite their sources.
Randomized trial demonstrates favorable safety and potential survival benefit of STSA-1002 in viral pneumonia ARDS, suggesting the need for phase 3 testing.
BACKGROUND: ARDS constitutes a major cause of mortality, with limited therapeutic options. RESEARCH QUESTION: Is STSA-1002 safe and clinically beneficial in ARDS caused by viral pneumonia? STUDY DESIGN AND METHODS: > 200 mm Hg, maintained for at least 48 hours, whichever occurred first, within 28 days. The 28-day all-cause mortality was 5.88% (1 of 17), 26.67% (4 of 15), and 40% (6 of 15). STSA-1002 was well tolerated. INTERPRETATION: STSA-1002 exhibited a favorable safety profile and potential efficacy. These findings warrant confirmation in a phase 3 trial. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT06038916; URL: www. CLINICALTRIALS: gov.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: